TY - JOUR
T1 - Towards digital solutions for tinnitus
T2 - a randomized controlled trial of the Oto smartphone application
AU - Mui, Boaz
AU - Muzaffar, Jameel
AU - Chen, Jinsong
AU - Bidargaddi, Niranjan
AU - Shekhawat, Giriraj Singh
PY - 2025/3
Y1 - 2025/3
N2 - To evaluate the effectiveness and usability of the Oto smartphone app in reducing tinnitus severity and distress. A prospective, unblinded randomized controlled trial (ANZCTR registration number: ACTRN12623001138673) with two arms: (i) intervention, and (ii) wait list control. Intervention arm received subscription to Oto. Ninety-six Australian adults experiencing chronic tinnitus (≥6 months). The overall TFI score in the intervention group showed statistically significant improvement compared to the control group from baseline to 6 months (mean decrease = 9 points, p =.006, 95% CI [2, 16]). A significantly higher proportion of intervention group (32%) reported clinically meaningful reduction in overall TFI score (≥13 points) than control group (12%) at 6 months, z = 2.20, p =.030. Significant interaction effects (time x treatment group) in overall TFI score were observed at 6 months, p <.001, Cohen’s d = 0.62, and 9 months, p =.002, Cohen’s d = 0.54. App usability was rated high on the mHealth App Usability Questionnaire (MAUQ) at 5.1 out of 7. Overall dropout rate was 21%. Use of Oto was effective in reducing tinnitus severity and distress. Future evaluation should consider including a wider range of tinnitus-related outcome measures and collection of qualitative data on user experience. Trial registration:Australian New Zealand Clinical Trials Registry identifier: ACTRN12623001138673.
AB - To evaluate the effectiveness and usability of the Oto smartphone app in reducing tinnitus severity and distress. A prospective, unblinded randomized controlled trial (ANZCTR registration number: ACTRN12623001138673) with two arms: (i) intervention, and (ii) wait list control. Intervention arm received subscription to Oto. Ninety-six Australian adults experiencing chronic tinnitus (≥6 months). The overall TFI score in the intervention group showed statistically significant improvement compared to the control group from baseline to 6 months (mean decrease = 9 points, p =.006, 95% CI [2, 16]). A significantly higher proportion of intervention group (32%) reported clinically meaningful reduction in overall TFI score (≥13 points) than control group (12%) at 6 months, z = 2.20, p =.030. Significant interaction effects (time x treatment group) in overall TFI score were observed at 6 months, p <.001, Cohen’s d = 0.62, and 9 months, p =.002, Cohen’s d = 0.54. App usability was rated high on the mHealth App Usability Questionnaire (MAUQ) at 5.1 out of 7. Overall dropout rate was 21%. Use of Oto was effective in reducing tinnitus severity and distress. Future evaluation should consider including a wider range of tinnitus-related outcome measures and collection of qualitative data on user experience. Trial registration:Australian New Zealand Clinical Trials Registry identifier: ACTRN12623001138673.
KW - mobile health (mHealth)
KW - randomized controlled trial
KW - smartphone applications (apps)
KW - teleaudiology
KW - Tinnitus
UR - http://www.scopus.com/inward/record.url?scp=105009833278&partnerID=8YFLogxK
U2 - 10.1080/2050571X.2025.2526235
DO - 10.1080/2050571X.2025.2526235
M3 - Article
AN - SCOPUS:105009833278
SN - 2050-571X
VL - 28
JO - Speech, Language and Hearing
JF - Speech, Language and Hearing
IS - 1
M1 - 2526235
ER -